About us

IsomAb is a Nottingham and Cambridge, UK-based biotechnology company developing isoform-specific antibodies for cardiovascular diseases. Founded in 2022 as a spin-out from the University of Nottingham, its early research was supported by the British Heart Foundation, Wellcome Trust, and Medical Research Council.

The Company is led by a highly experienced management team, and has a strong scientific foundation, with multi-disciplinary experience in antibody development and manufacture.

The Company is supported by an international Clinical Advisory Board comprising renowned cardiovascular specialists.

Our Investors are focused in the biotech and technology sectors with a real-world understanding of the challenges and provide valuable strategic advice.